249 related articles for article (PubMed ID: 12516939)
1. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
Simon MW; Fish DN; Deeter RG
Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
[TBL] [Abstract][Full Text] [Related]
2. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
Perry CM; Faulds D
Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
[TBL] [Abstract][Full Text] [Related]
5. Valaciclovir: a review of its use in the management of herpes zoster.
Ormrod D; Goa K
Drugs; 2000 Jun; 59(6):1317-40. PubMed ID: 10882165
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects.
Gimenez F; Foeillet E; Bourdon O; Weller S; Garret C; Bidault R; Singlas E
Clin Pharmacokinet; 2004; 43(10):685-92. PubMed ID: 15244498
[TBL] [Abstract][Full Text] [Related]
7. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.
Bodsworth NJ; Crooks RJ; Borelli S; Vejlsgaard G; Paavonen J; Worm AM; Uexkull N; Esmann J; Strand A; Ingamells AJ; Gibb A
Genitourin Med; 1997 Apr; 73(2):110-6. PubMed ID: 9215092
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
Jacobson MA; Gallant J; Wang LH; Coakley D; Weller S; Gary D; Squires L; Smiley ML; Blum MR; Feinberg J
Antimicrob Agents Chemother; 1994 Jul; 38(7):1534-40. PubMed ID: 7979285
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.
Kimberlin DW; Jacobs RF; Weller S; van der Walt JS; Heitman CK; Man CY; Bradley JS
Clin Infect Dis; 2010 Jan; 50(2):221-8. PubMed ID: 20014952
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients.
Stathoulopoulou F; Dhillon S; Thodis H; Stathakis C; Vargemezis V
Nephron; 2002 May; 91(1):164-6. PubMed ID: 12021536
[TBL] [Abstract][Full Text] [Related]
12. A new paediatric formulation of valaciclovir: development and bioequivalence assessment.
Bastiaans DE; Bartels-Wilmer CM; Colbers AP; Heijens CA; Velthoven-Graafland K; Smeets OS; Vink N; Harbers VE; Warris A; Burger DM
Arch Dis Child; 2016 Oct; 101(10):971-2. PubMed ID: 27162003
[No Abstract] [Full Text] [Related]
13. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients.
Höglund M; Ljungman P; Weller S
J Antimicrob Chemother; 2001 Jun; 47(6):855-61. PubMed ID: 11389118
[TBL] [Abstract][Full Text] [Related]
14. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
Johnston C; Saracino M; Kuntz S; Magaret A; Selke S; Huang ML; Schiffer JT; Koelle DM; Corey L; Wald A
Lancet; 2012 Feb; 379(9816):641-7. PubMed ID: 22225814
[TBL] [Abstract][Full Text] [Related]
15. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.
Helldén A; Lycke J; Vander T; Svensson JO; Odar-Cederlöf I; Ståhle L
J Antimicrob Chemother; 2006 May; 57(5):945-9. PubMed ID: 16540518
[TBL] [Abstract][Full Text] [Related]
16. Valaciclovir (BW256U87): the L-valyl ester of acyclovir.
Jacobson MA
J Med Virol; 1993; Suppl 1():150-3. PubMed ID: 8245883
[TBL] [Abstract][Full Text] [Related]
17. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
Ormrod D; Scott LJ; Perry CM
Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
[TBL] [Abstract][Full Text] [Related]
18. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
Soul-Lawton J; Seaber E; On N; Wootton R; Rolan P; Posner J
Antimicrob Agents Chemother; 1995 Dec; 39(12):2759-64. PubMed ID: 8593015
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
Steingrimsdottir H; Gruber A; Palm C; Grimfors G; Kalin M; Eksborg S
Antimicrob Agents Chemother; 2000 Jan; 44(1):207-9. PubMed ID: 10602752
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus.
Colin J; Prisant O; Cochener B; Lescale O; Rolland B; Hoang-Xuan T
Ophthalmology; 2000 Aug; 107(8):1507-11. PubMed ID: 10919899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
